A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
To evaluate the efficacy and safety of cadonilimab combined with Regorafenib in patients with hepatocellular carcinoma who failed camrelizumab plus apatinib.
Hepatocellular Carcinoma
DRUG: Cadonilimab+regorafenib
objective response rate (ORR) per RECIST1.1, The proportion of all subjects with the best overall response (BOR) as complete remission (CR) or partial remission (PR) according to RECIST 1.1 criteria., Up to two years
Progression-free survival（PFS）, PFS was defined as the time from the first dose to the time of the first documented tumor progression (assessed by RECIST1.1 criteria) or the time of death from any cause, whichever occurred first., Up to two years|Overall survival（OS）, Defined as the time from the first dose to the death from any cause., Up to three years|Duration of response (DOR), Defined as the time from the first dose to disease progression or death in patients who achieve complete or partial response, Up to two years|Occurence of AE and SAE, Occurence of Adverse Event (AE) and Serious Adverse Event (SAE) （NCI CTCAE 5.0）, Up to two years
To evaluate the efficacy and safety of cadonilimab combined with Regorafenib in patients with hepatocellular carcinoma who failed camrelizumab plus apatinib.